Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Latest biopharmaceutical Stories

2013-09-12 08:31:23

Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets DALLAS and NEW YORK, Sept. 12, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the European Patent Office that an additional European patent for MuGard(TM) has been granted. The patent (EP1997478) protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and...

2013-09-11 16:25:01

- new Board to oversee sale of Animal Health and sale/partnering of VMC with commitment to return capital to shareholders - BELLEVILLE, ON, Sept. 11, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company and concerned shareholders William (Bill) M. Wells and Greg Gubitz today jointly announced that they have reached a settlement that both sides believe is beneficial to all of the Company's...

2013-09-11 12:25:03

BELLEVILLE, ON, Sept. 11, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today issued an open letter to all shareholders from Founder, President & CEO, Graeme McRae, regarding his going forward role with the Company: Dear Fellow Shareholders, I am writing to advise you of my changing role with Bioniche Life Sciences Inc., the Company I founded with the support of 100 Ontario...

2013-09-11 12:24:59

Company's Interrogative Biology(TM) Platform Recognized for Breakthrough, Data-Driven Scientific Approach BOSTON, Sept. 11, 2013 /PRNewswire/ -- Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach, was recognized today with the 2013 North American Drug Discovery Technology Innovation Award at the Frost & Sullivan Growth, Innovation and Leadership Awards Gala, the annual event by the global research...

2013-09-10 08:29:18

BALTIMORE, Sept. 10, 2013 /PRNewswire/ -- Paragon Bioservices, a contract manufacturing organization whose expertise is the process development and manufacturing of biopharmaceuticals, announced today that it has been awarded the 2013 CMO Leadership Award for Quality and Reliability. "We are very honored to receive this award from Life Science Leader -- especially because this is our third consecutive year," said Dr Marco Chacon, Paragon's CEO. "For more than twenty years, we have...

2013-09-03 23:26:08

Freeslate System Supports the Exploration of Broader Formulation Experimental Space with a Reduced Material Requirement SUNNYVALE, Calif. (PRWEB) September 03, 2013 Freeslate, Inc., the leading provider of high throughput research solutions, today announced that KBI Biopharma, Inc. (KBI), a leading development and contract manufacturing organization serving the biopharmaceutical industry, has purchased Freeslate’s Biologics Formulation System to help develop more robust formulations...

2013-08-28 08:26:00

TOORAK, Australia, Aug. 28, 2013 /PRNewswire/ -- Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly. The investment and partnering focused conferences will involve...

2013-08-26 12:22:18

High-Titer Process Developed for New Antibody Therapeutic PRINCETON, N.J., Aug. 26, 2013 /PRNewswire/ -- Laureate Biopharma is pleased to announce its successful collaboration with Dyax Corp. for process development and cGMP production of a new treatment candidate for hereditary angioedema (HAE). The drug candidate, known as DX-2930, is a fully human IgG antibody designed to prevent HAE attacks by inhibition of plasma kallikrein. Dyax, a biopharmaceutical company focused...

2013-08-25 20:20:20

Attractive Addition to Amgen's Leading Oncology Portfolio and Pipeline THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Onyx...

2013-08-19 12:24:59

Company names J. Kevin Buchi President and Chief Executive Officer, Pete A. Meyers Chief Financial Officer, and Lesley Russell, MBChB, MRCP Chief Operating Officer MALVERN, Pa., Aug. 19, 2013 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule SMAC mimetic drugs to treat cancer, today announced the appointment of a new senior executive leadership team with the goal of accelerating the development of the company and its lead product...